A record of what Jefferies Analysis said publicly, with the source. Not advice.
“Bullish on Piramal Pharma, setting a target of ₹260, indicating an almost 30% potential upside. The stock's valuation discount relative to peers makes it an attractive bet, despite a 15% drop over the past year.”
Jefferies Analysis’s track record (trackable calls only): 153 graded calls · 95% CI 37–53%
Piramal Pharma LtdBullishCalled 15 Sep 2025Graded 15 Sep 2026
R4 TARGET_CALL: entered ₹205.63 on 2025-09-16 (next trading session's close); neither target nor stop reached by window end 2026-09-15. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.
How it played out
How this is worked out- Time to target
- The target was not reached on a close inside the window.
- Worst close against it
- The closing price went as far as 35.19% against the call up to 15 Sep 2026, when the call was decided, measured from the entry price. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.